Navigation Links
New England Biolabs Launches a Suite of Innovative Tools to Advance Epigenetics Research, Including PCR-Based Assay to Identify and Quantitate 5-hmC in Epigenome
Date:10/14/2010

IPSWICH, Mass., Oct. 14 /PRNewswire/ -- New England Biolabs (NEB) has launched a suite of new and validated products designed to simplify DNA methylation analysis for epigenetics researchers. These enzyme-based solutions address some of the challenges of the current methods, including the lack of a reproducible method for the analysis and quantitation of 5-hydroxymethlcytosine (5-hmC) in the epigenome.

(Logo: http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090921/NE79207LOGO-b)

EpiMark™ validated products from NEB include a family of methylation-dependent restriction enzymes (MspJI, FspEI and LpnPI), which excise 32-base pair fragments from whole genomes. These fragments contain centrally located hydroxymethylated (5-hmC) or methylated (5-mC) residues, and can be subsequently extracted and sequenced. This method is less harsh than bisulfite conversion and is suitable for whole methylome analysis.

The EpiMark™ 5-hmC and 5-mC Analysis Kit is a robust method for the identification and detection of 5-hmC and 5-mC within a specific locus. This three-step protocol reproducibly identifies and quantitates the presence of 5-hmC. Additionally, it is compatible with existing analysis techniques and is amenable to high throughput.

"Epigenetics currently represents one of the most exciting areas of life science research," states Andy Bertera, Director of Marketing at New England Biolabs. "The availability of innovative tools that simplify epigenetic studies is critical for the development of new disease-related biomarkers. The EpiMark family of products will help to achieve this, as well as help to further our understanding of the role of 5-hmC in the epigenome."

About NEB

Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company, headquartered in Ipswich, MA and has extensive worldwide distribution through a network of exclusive distributors, agents and five subsidiaries located in Canada, China, Germany, Japan and the UK. For more information about New England Biolabs visit www.neb.com.


'/>"/>
SOURCE New England Biolabs
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New England Biolabs Receives Award to Develop Novel Enzymatic Reagents for Epigenetic Studies
2. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
3. New England Biolabs Launches NEBNext™ Quick DNA Sample Prep Reagent Sets for Use With Roche/454 Next Generation Sequencing Platforms
4. The New England Journal of Medicine Publishes Results of Landmark CREST Study, Showing Similar Positive Outcomes for Abbotts Carotid Stent System and Surgery
5. Whistleblower Lawyers Comment on New England Journal of Medicine Study
6. STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
7. Millennium Pharmacy Adds First Client in New England
8. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
9. Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine
10. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
11. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the 2009 British Pharmaceutical Conference in Manchester, England
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):